Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels
- PMID: 10330139
- PMCID: PMC104358
- DOI: 10.1128/MCB.19.6.3989
Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels
Abstract
The human telomerase RNA component (hTR) is present in normal somatic cells at lower levels than in cancer-derived cell lines. To understand the mechanisms regulating hTR levels in different cell types, we have compared the steady-state hTR levels in three groups of cells: (i) normal telomerase-negative human diploid cells; (ii) normal cells transfected with the human telomerase catalytic subunit, hTERT; and (iii) cells immortalized in vitro and cancer cells expressing their own endogenous hTERT. To account for the differences in steady-state hTR levels observed in these cell types, we compared the transcription rate and half-life of hTR in a subset of these cells. The half-life of hTR in telomerase-negative cells is about 5 days and is increased 1.6-fold in the presence of hTERT. The transcription rate of hTR is essentially unchanged in cells expressing exogenous hTERT, and the increased steady-state hTR level appears to be due to the increased half-life. However, the transcription rate of hTR is greatly increased in cells expressing endogenous hTERT, suggesting some overlap in transcriptional regulatory control. We conclude that the higher hTR level in cells expressing an endogenous telomerase can be a result of both increased transcription and a longer half-life and that the longer half-life might be partially a result of protection or stabilization by the telomerase catalytic subunit. The 4-week half-life of hTR in H1299 tumor cells is the longest half-life yet reported for any RNA.
Figures





Similar articles
-
Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells.Nucleic Acids Res. 2001 Dec 1;29(23):4818-25. doi: 10.1093/nar/29.23.4818. Nucleic Acids Res. 2001. PMID: 11726691 Free PMC article.
-
[Combination of antisense human telomerase RNA and antisense human telomerase catalytic subunit inhibits cervical cancer Hela cells growth].Zhonghua Fu Chan Ke Za Zhi. 2005 Jan;40(1):42-6. Zhonghua Fu Chan Ke Za Zhi. 2005. PMID: 15774092 Chinese.
-
Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions.Mol Cell Biol. 2001 Mar;21(5):1888-97. doi: 10.1128/MCB.21.5.1888-1897.2001. Mol Cell Biol. 2001. PMID: 11238925 Free PMC article.
-
Expression of telomerase genes in thyroid carcinoma.Int J Oncol. 2002 Aug;21(2):265-72. Int J Oncol. 2002. PMID: 12118320 Review.
-
How RNAi machinery enters the world of telomerase.Cell Cycle. 2019 May;18(10):1056-1067. doi: 10.1080/15384101.2019.1609834. Epub 2019 May 7. Cell Cycle. 2019. PMID: 31014212 Free PMC article. Review.
Cited by
-
Implications of telomerase reverse transcriptase in tumor metastasis.BMB Rep. 2020 Sep;53(9):458-465. doi: 10.5483/BMBRep.2020.53.9.108. BMB Rep. 2020. PMID: 32731912 Free PMC article. Review.
-
Telomere length homeostasis requires that telomerase levels are limiting.EMBO J. 2006 Feb 8;25(3):565-74. doi: 10.1038/sj.emboj.7600952. Epub 2006 Jan 19. EMBO J. 2006. PMID: 16424902 Free PMC article.
-
Natural and pharmacological regulation of telomerase.Nucleic Acids Res. 2002 Feb 15;30(4):839-65. doi: 10.1093/nar/30.4.839. Nucleic Acids Res. 2002. PMID: 11842096 Free PMC article. Review.
-
Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells.Cancer Sci. 2008 Jun;99(6):1092-9. doi: 10.1111/j.1349-7006.2008.00815.x. Cancer Sci. 2008. PMID: 18482052 Free PMC article. Review.
-
Quantification of Pseudouridine Levels in Cellular RNA Pools with a Modified HPLC-UV Assay.Genes (Basel). 2017 Sep 5;8(9):219. doi: 10.3390/genes8090219. Genes (Basel). 2017. PMID: 28872587 Free PMC article.
References
-
- Avilion A A, Piatyszek M A, Gupta J, Shay J W, Bacchetti S, Greider C W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 1996;56:645–650. - PubMed
-
- Beattie T L, Zhou W, Robinson M O, Harrington L. Reconstitution of human telomerase activity in vitro. Curr Biol. 1998;8:177–180. - PubMed
-
- Blasco M A, Lee H W, Hande M P, Samper E, Lansdorp P M, DePinho R A, Greider C W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 1997;91:25–34. - PubMed
-
- Bodnar A G, Ouellette M, Frolkis M, Holt S E, Chiu C P, Morin G B, Harley C B, Shay J W, Lichtsteiner S, Wright W E. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349–352. - PubMed
-
- Bryan T M, Marusic L, Bacchetti S, Namba M, Reddel R R. The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum Mol Genet. 1997;6:921–926. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources